Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Basilea Pharmaceutica Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Basilea Pharmaceutica kazanç ve gelirin sırasıyla yıllık 34.4% ve 9.2% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 34.7% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 83.8% olacağı tahmin edilmektedir.

Anahtar bilgiler

34.4%

Kazanç büyüme oranı

34.7%

EPS büyüme oranı

Biotechs kazanç büyümesi	35.6%
Gelir büyüme oranı	9.2%
Gelecekteki özkaynak getirisi	83.8%
Analist kapsamı	Good
Son güncelleme	27 Sep 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Apr 18

Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?

Sep 20

Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)

Feb 17

Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)

Jul 01

Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long

Mar 24

If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%

Feb 18

Kazanç ve Gelir Büyüme Tahminleri

SWX:BSLN - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CHF Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	240	75	N/A	46	2
12/31/2025	215	41	42	20	5
12/31/2024	203	60	15	37	2
6/30/2024	149	-1	9	10	N/A
3/31/2024	153	5	11	12	N/A
12/31/2023	158	10	13	14	N/A
9/30/2023	166	33	20	22	N/A
6/30/2023	175	56	27	29	N/A
3/31/2023	161	34	16	18	N/A
12/31/2022	148	12	4	7	N/A
9/30/2022	150	6	-2	1	N/A
6/30/2022	152	1	-8	-5	N/A
3/31/2022	150	-3	-20	-18	N/A
12/31/2021	148	-7	-33	-32	N/A
9/30/2021	130	-26	-41	-40	N/A
6/30/2021	112	-45	-50	-48	N/A
3/31/2021	120	-30	-53	-51	N/A
12/31/2020	128	-15	-56	-54	N/A
9/30/2020	134	-6	-55	-53	N/A
6/30/2020	141	3	-53	-52	N/A
3/31/2020	137	-10	-58	-58	N/A
12/31/2019	134	-22	-64	-64	N/A
9/30/2019	135	-23	-64	-64	N/A
6/30/2019	136	-24	-65	-64	N/A
3/31/2019	134	-28	-72	-72	N/A
12/31/2018	133	-31	-80	-79	N/A
9/30/2018	124	-26	-43	-42	N/A
6/30/2018	115	-21	-6	-5	N/A
3/31/2018	108	-20	N/A	7	N/A
12/31/2017	102	-19	N/A	19	N/A
9/30/2017	92	-32	N/A	-19	N/A
6/30/2017	82	-44	N/A	-58	N/A
3/31/2017	74	-48	N/A	-66	N/A
12/31/2016	66	-51	N/A	-75	N/A
9/30/2016	62	-55	N/A	-89	N/A
6/30/2016	58	-59	N/A	-102	N/A
3/31/2016	55	-61	N/A	-85	N/A
12/31/2015	53	-62	N/A	-68	N/A
9/30/2015	50	-57	N/A	-57	N/A
6/30/2015	47	-52	N/A	-46	N/A
3/31/2015	45	-47	N/A	-59	N/A
12/31/2014	42	-42	N/A	-71	N/A
9/30/2014	42	-38	N/A	-71	N/A
6/30/2014	41	-35	N/A	-71	N/A
3/31/2014	41	-34	N/A	-65	N/A
12/31/2013	41	-33	N/A	-59	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: BSLN önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 0.3% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: BSLN önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: BSLN önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: BSLN şirketinin gelirinin (yıllık 9.2% ) Swiss pazarından (yıllık 4.4% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: BSLN şirketinin gelirinin (yıllık 9.2% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: BSLN 'nin Özsermaye Getirisi'nin 3 yıl içinde çok yüksek olması tahmin ediliyor ( 83.8 %).

Basilea Pharmaceutica Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Basilea Pharmaceutica AG Updates Financial Guidance for the Year 2024

Consensus EPS estimates increase by 15%

Price target increased by 7.6% to CHF70.58

Consensus EPS estimates fall by 78%

Price target decreased by 7.6% to CHF69.90

Consensus EPS estimates fall by 30%

Recent updates

Basilea Pharmaceutica AG Updates Financial Guidance for the Year 2024

European Commission Approves the Pediatric Use of Basilea Pharmaceutica AG's Antifungal Cresemba® (Isavuconazole)

First half 2024 earnings: EPS exceeds analyst expectations

New minor risk - Share price stability

Basilea Reports Presentation of New Data for Ceftobiprole (Zevtera®) At Escmid Global 2024

Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Consensus EPS estimates increase by 15%

Price target increased by 7.6% to CHF70.58

Basilea Pharmaceutica AG to Report First Half, 2024 Results on Aug 13, 2024

New minor risk - Negative shareholders equity

Full year 2023 earnings: EPS exceeds analyst expectations

New minor risk - Share price stability

Consensus EPS estimates fall by 78%

Price target decreased by 7.6% to CHF69.90

Consensus EPS estimates fall by 30%

Basilea Pharmaceutica AG to Report Fiscal Year 2023 Results on Feb 13, 2024

Basilea Pharmaceutica AG, Annual General Meeting, Apr 24, 2024

Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?

Basilea Pharmaceutica AG Revises Earnings Guidance for the Year 2023

First half 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Price target decreased by 9.0% to CHF67.18

Consensus EPS estimates increase by 13%

Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)

Basilea Pharmaceutica AG to Report First Half, 2023 Results on Aug 15, 2023

Basilea Pharmaceutica Ltd Revises Earnings Guidance for the Year 2022

Basilea Pharmaceutica AG, Annual General Meeting, Apr 26, 2023

Basilea Pharmaceutica AG to Report Fiscal Year 2022 Results on Feb 14, 2023

Price target decreased to CHF68.58

Price target decreased to CHF68.58

Basilea Pharmaceutica AG 's ERADICATE Phase 3 Study Results Highlight the Potential Role of Ceftobiprole in the Treatment of Staphylococcus Aureus Bacteremia (Sab)

Consensus estimates of losses per share improve by 13%

Consensus estimates of losses per share improve by 10%

Basilea Pharmaceutica AG Revises Earnings Guidance for the Full Year 2022

Price target increased to CHF73.98

First half 2022 earnings: EPS and revenues exceed analyst expectations

Basilea Pharmaceutica AG Provides Earnings Guidance for the Year 2022

Basilea Pharmaceutica AG Provides Earnings Guidance for the Year 2022

Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)

Consensus forecasts updated

Basilea Pharmaceutica Ltd. Positive Results of Phase 3 Eradicate Study with Ceftobiprole in Staphylococcus Aureus Bacteremia

Basilea Pharmaceutica AG Reports Progress on the Implementation of Its Strategy to Focus on Anti-Infectives

Basilea Pharmaceutica AG to Report First Half, 2022 Results on Aug 16, 2022

High number of new directors

Price target decreased to CHF77.00

Insufficient new directors

Basilea Pharmaceutica Ltd. Approves Appointment of Leonard Kruimer as New Member of Board and as Chairman of the Audit Committee

Basilea Pharmaceutica Ltd. Reports Preclinical Data on Oncology Drug Candidates BAL0891

Price target decreased to CHF77.50

Basilea Reports Preclinical Data on Anti-Cancer Activity of Novel Oncology Drug Candidate BAL0891 at ESMO TAT congress

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Forecast breakeven date moved forward to 2023

Basilea Pharmaceutica AG Provides Earnings Guidance for the Fiscal Year 2022

Basilea Reports Updated Interim Results for iCCA Patients with FGFR2 Mutations and Amplifications from Phase 2 Study FIDES-01 at ASCO GI Cancers Symposium

Basilea Announces Completion of Patient Enrolment in Phase 3 Eradicate Study Investigating Ceftobiprole in Bloodstream Infections

Forecast to breakeven in 2024

Basilea Pharmaceutica Ltd. Announces FDA Approval of Investigational New Drug Application for Novel Oncology Drug Candidate BAL0891

Basilea Pharmaceutica Ltd. Presents Full Safety and Efficacy Data Set on Derazantinib in Patients with FGFR2 Fusion-Positive iCCA at ESMO Congress

First half 2021 earnings released: CHF1.72 loss per share (vs CHF0.92 profit in 1H 2020)

No longer forecast to breakeven

Basilea Pharmaceutica Ltd. Provides Updates on Efficacy Data with Derazantinib in Bile Duct Cancer and on Ongoing Clinical Programs in Urothelial and Gastric Cancer

Basilea Pharmaceutica AG Wins Carb-X Grant of Up to USD 2.7 Million to Develop Novel-Class Antibiotic

Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long

Basilea Pharmaceutica AG has completed a Follow-on Equity Offering in the amount of CHF 45.75 million.

If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%

PHT International Inc. entered into an agreement to acquire Basilea Pharmaceutica China Ltd. from Basilea Pharmaceutica AG (SWX:BSLN) for $6.3 million.

Basilea Pharmaceutica Ltd. Reports derazantinib/PD-L1 Checkpoint Inhibitor Combination Results from Dose-Finding Part of FIDES-02 Study in Patients with Solid Tumors at ASCO GU Symposium

Basilea Pharmaceutica Ltd. Promotes Potential First-In-Class Small-Molecule Kinase Inhibitor